Take heed nuc med labs. The British have come up with a smashing idea: an instrument that allows medical physicists to make sure the instruments they use to check the doses of radioactive compounds are themselves accurate.
Take heed nuc med labs. The British have come up with a smashing idea: an instrument that allows medical physicists to make sure the instruments they use to check the doses of radioactive compounds are themselves accurate.
The device, Fidelis, is a computer-controlled electrometer married to a gas-filled chamber set between two conducting electrodes. When a radioactive source is placed near the chamber, gamma rays emitted by the source ionize the gas, creating a current that can be measured by the high-resolution, high-linearity electrometer. The chamber was designed by the National Physical Laboratory, the U.K.'s national measurement institute.
Developed and brought to the market by Southern Scientific, Fidelis serves as an example of the applied technology program of NPL, which licenses government-owned technology to the private sector.
The finished product has been available for several months, but only now is the company beginning to promote its value through a marketing campaign that describes Fidelis as "the next-generation radionuclide calibrator with unsurpassed accuracy and traceability."
Many hospitals use radionuclide calibrators that need recalibrating whenever new applications or newly designed vials come along. Fidelis needs no such attention, according to Southern Scientific.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.